On May 18, 2023, the FDA’s vaccine committee met to vote on whether Pfizer’s new RSV vaccine is “safe” and “effective.” Ahead of that meeting, ICAN, through its attorneys, wrote a letter to the FDA committee members to warn about numerous serious issues evident from its clinical trial, including the low efficacy, significant adverse events, and lack of a placebo […]